Michael Webber
Psychiatry · Carmel, INNPI 1114197613
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 608 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 24.2% of the total. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 608 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$654
- Vanda Pharmaceuticals Inc.$642
- Supernus Pharmaceuticals, Inc.$590
- Sunovion Pharmaceuticals Inc.$566
- Otsuka America Pharmaceutical, Inc.$564
- plus $4K from 27 others
What the payments were for
- Food & beverage$9,20899%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $2,252 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $654 |
| Vanda Pharmaceuticals Inc. | 24 | $642 |
| Supernus Pharmaceuticals, Inc. | 127 | $590 |
| Sunovion Pharmaceuticals Inc. | 57 | $566 |
| Otsuka America Pharmaceutical, Inc. | 25 | $564 |
| Neurocrine Biosciences, Inc. | 26 | $477 |
| Ironshore Pharmaceuticals Inc. | 29 | $445 |
| Axsome Therapeutics, Inc. | 22 | $413 |
| Corium, LLC | 16 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $311 |
| Johnson & Johnson | 14 | $277 |
| Teva Pharmaceuticals USA, Inc. | 13 | $253 |
| Lundbeck LLC | 13 | $184 |
| Neos Therapeutics, LP | 8 | $140 |
| Arbor Pharmaceuticals, Inc. | 1 | $140 |
| Bausch Health US, LLC | 9 | $134 |
| Jazz Pharmaceuticals Inc. | 6 | $123 |
| Adlon Therapeutics L.p. | 8 | $121 |
| Checkpoint Surgical, Inc | 1 | $117 |
| Noven Therapeutics, LLC | 6 | $117 |
| Zimmer Biomet | 1 | $104 |
| Vertical Pharmaceuticals, LLC | 5 | $94 |
| Alkermes, Inc. | 5 | $77 |
| Shire North American Group Inc | 3 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Almatica Pharma LLC | 1 | $20 |
| Harmony Biosciences LLC | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Sage Therapeutics, LLC | 1 | $12 |
| Tris Pharma Inc | 1 | $12 |
| Indivior Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,316 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $90,136 |
| Abilify MaintenaAripiprazole | 12 | $27,150 |
| TrintellixVortioxetine Hydrobromide | 16 | $9,149 |
| FanaptIloperidone | 13 | $7,037 |
| Aripiprazole | 32 | $4,527 |
| Bupropion Hcl SrBupropion Hcl | 24 | $2,873 |
| Ziprasidone Hcl | 32 | $1,549 |
| Armodafinil | 14 | $1,495 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $1,465 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $1,461 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $1,378 |
| Buspirone Hcl | 46 | $1,287 |
| Bupropion XlBupropion Hcl | 25 | $940 |
| Olanzapine | 18 | $892 |
| Duloxetine Hcl | 14 | $760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $477 | $90,13612 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $564 | $27,15012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $311 | $9,14916 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $642 | $7,03713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Carmel
- Steven PaulCarmel$2.9M
- Christopher BojrabCarmel$713K
- Michael DetkeCarmel$14K
- Tyler FlaninghamCarmel$7K
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.